Evidence map›Paper›PMID 42254369›Full record

ArticleFrontiers in medicine2026

DeepInsight-Net: a CBAM-enhanced ResNet50 framework with focal loss for robust cervical cancer classification on multi-center datasets.

Elif İlgazi Kılıç, Şafak Kılıç

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Elif İlgazi KılıçKayseri City Hospital, Department of Obstetrics and Gynecology, Kayseri, Türkiye.
Şafak KılıçDepartment of Computer Science, CHART Laboratory, University of Nottingham, Nottingham, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cervical cancer remains one of the leading causes of gynecological mortality worldwide, largely due to the limitations of manual cytological screening, which is time-consuming and susceptible to inter-observer variability. Although deep learning has demonstrated strong potential for automating cervical cytopathology, existing Convolutional Neural Network (CNN) models are hindered by two critical challenges: Methods: To address these limitations, we propose DeepInsight-Net, a robust three-stage deep learning framework for cervical cell classification. The core architecture integrates Convolutional Block Attention Modules (CBAM) into a ResNet50 backbone to enhance spatial and channel-wise feature discrimination, enabling the network to selectively emphasize nuclear and nuclear-cytoplasmic boundary regions while suppressing irrelevant background noise. To further mitigate class imbalance, the conventional cross-entropy loss is replaced with Focal Loss, which dynamically down-weights easily classified samples and prioritizes hard, misclassified instances during training. Results: Extensive experiments conducted on the benchmark SiPaKMeddataset demonstrate that DeepInsight-Net achieves a state-of-the-art classification accuracy of 99.63%, outperforming 15 competitive deep learning models, including EfficientNet-B6 and DenseNet169. Moreover, cross-dataset generalization experiments on an independent Liquid-Based Cytology (LBC) dataset yield an accuracy of 98.62%, confirming the robustness and domain adaptability of the proposed framework. Visual interpretability analyses using Grad-CAM and t-SNE reveal that the model consistently focuses on biologically relevant cellular regions, supporting the reliability of its predictions. Conclusion: The proposed DeepInsight-Net effectively addresses spatial irrelevance and class imbalance in cervical cytology analysis through attention-guided feature learning and loss re-weighting. The strong performance across multiple datasets, combined with transparent visual explainability, highlights its potential as a reliable computer-aided diagnosis (CAD) tool for supporting cervical cancer screening in real-world clinical settings.

Indexed as

CBAMcervical cancerdeep learningfocal lossPap smearResNet50

Identifiers

PMID42254369
PMCPMC13234920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.